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Abstract 
 
The goal of this investigation is to analyze the bibliographical references that are registered in the IEDB database 
regarding the linear B-cell epitopes responsible for Plasmodium falciparum malaria in humans during the temporal 
period 1984 to 2018. The geographical origin of the samples and the relevant journals were obtained for the linear 
B-cell epitopes in Plasmodium falciparum according to the Similarity Index. This methodology can be applied to 
another disease. 
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Introduction 
 
Malaria is transmitted by the protozoan parasite 
Plasmodium and it is transmitted among humans by the 
female mosquitoes Anopheles gambiae. Plasmodium 
belongs to the phylum Apicomplexa and the 
Plasmodiidae family. Only five species affect humans 
where four of them are anthroponotic (Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae 
and Plasmodium ovale) and one by zoonotic that also 
affects primates (genus Macaca). 
In 2016, approximately 216 million cases of malaria 
(or paludism) were reported worldwide according to 
the World Malaria Report 2017 [1], and of all of them, 
P. falciparum is responsible for most of the clinical 
manifestations throughout the world (90% of the fatal 
cases). They mainly occurred in Africa, while that P. 
vivax is the principal species that is found in America. 
At the present time, there is a vaccine that is currently 
in phase III of clinical trials and it is the pre-
erythrocytic vaccine called RTS,S (MosquirixTM) [2].  
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It's effectiveness has yet to be demonstrated totally. For 
this reason, we reviewed the scientific literature of all 
the scientific studies presented in the database called 
IEDB [3] and delayed including it until September, 
2018 and focused only on the availability of vaccines. 
In fact, this type of study allows one to create new 
vaccines based on B cell epitopes against malaria 
caused by Plasmodium falciparum such as  [4-7] 
The Immune Epitope Database (abbreviated IEDB and 
available at iedbr.org) which issponsored by the 
National Institute of Allergy and Infectious Diseases 
(NIAID) for the last 14 years [3]. It is a repository of 
epitope of emerging diseases as well as in the 
bioterrorist threat. Until November 2018, this has 
included more than 19,818 publications and 471,390 B 
cell papers.  In addition, only publications appearing in 
peer-reviewed journals, patents or patent applications, 
and registered items are considered. For this reason, 
this work will analyze all the publications concerning 
linear epitopes B cells in humans in Plasmodium 
falciparum from 1984 until September 2018. 
Material & methods 
We select publications in the IEDB by P. falciparum 
based on linear B cells epitope whose host is human, 
and we determined: (1) the geographical origin of the 
samples, (2) the journals where the results were 
published, (3) the years of publication, (4) the antigens, 
and (5) the consensus of linear B cell epitope according 
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to the methodology published in the scientific 
literature.  The consensus selection will be the one with 
the highest value of the "Similarity Index".This index 
is calculated when aligning each of the epitopes present 
in each antigen, and we count the frequency at the 
positions of the amino acids in each epitope, divided by 
the total length of the epitope.The range of values is 
from zero (there is no consensus defined in all 
positions of the amino acids that make up the epitope) 
to 10.0 (identical). 
Results 
We obtained a file in CSV format (ie separated by a 
comma) from the IEDB database where 146 scientific 
journals with linear B cell epitopes whose host was a 
human in Plasmodium falciparum, which allow us to 
determine: 
 
Geographic origin
Figure 1 shows the geographic origin of the samples by 
continents where the majority of events comes from 
Africa (83.48%), followed by South America (6.63%), 
Asia (4, 94%), and so on. Finally, North America is the 
continent with the lowest number of samples registered 
by Plasmodium falciparum. 
 
 
Fig. 1:  Geographic origin of the samples according to IEDB 
Scientific journals 
The next analysis was to examine the scientific 
journals where the results are published with the 
condition being that three or more papers appear in 
same journal (Fig. 2).  The majority of the papers were 
published in the journal "Infection and Immunity" 
(total of 27 papers), followed by "The American 
Journal of Tropical Medicine and Hygiene" (17 
papers), "Parasite Immunology" (12 papers), "The 
Journal of Immunology" (9 papers), and so on. 
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Fig. 2:  Scientific journals with three or more papers have been published in malaria by Plasmodium 
falciparum in IEDB 
Year of publications 
The number of scientific publications per year is shown 
in Figure 3 during the period 1984 to September 2018. 
This figure shows an increase in 1991 and then the 
number fluctuates but decreases over time. From 2014 
until the present time, the number of papers that are 
published per year is constant. 
There is no one trend per year of scientific publications 
on P. falciparum malaria. In fact, in 1991, papers 
appeared in the following journals: Transactions of the 
Royal Society of Tropical Medicine and Hygiene, 
Parasite Immunology, Molecular and Biochemical 
Parasitology, The Journal of Immunology, Journal of 
Clinical Microbiology, International Immunology, 
Immunology Letters, Annals of Tropical Medicine and 
Parasitology, and American Journal of Epidemiology.
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Fig. 3:Total number of publications of linear B cell epitope by Plasmodium falciparum in human host per year 
Antigens 
Figure 4 shows the antigens according to the scientific 
journals according to IEDB, with the condition that 
they appear in four or more articles in a journal. This 
result reveals that the majority of papers is 
Circumsporozoitic and later DNAJ. 
 
 
Fig. 5: Antigens present in the publications registered in IEDB 
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Consensus linear B-cell epitope and Similarity Index 
There are 985 epitopes in the 146 scientific journals 
and they are grouped by antigens in Table 1. For 
example, 101 kDa malaria antigen has 6 linear B-cell 
epitope in the IEDB corresponding to Plasmodium 
falciparum (human host). These six epitopes are all 
shown with the IEDB ID in the second column of 
Table 1.  However, when there is a large number of 
epitopes the list is truncated, i.e., membrane protein 1 
with 137 epitopes. 
The first and second column of Table 1 corresponds to 
name and ID antigen, respectively. The third column 
indicates the consensus epitope according to the 
highest value of the Similarity Index  (X means any 
amino acid). For this reason, the epitopes that are not 
considered in the consensus are crossed out in column 
2.   
For example, liver stage antigens there are twelve 
linear B cell epitopes.  The consensus formed by the 
epitope ID: 7763, 7818, 9449, 11799, 24930, 43702 is 
D- [E / L] -D- [E / L] –G-I-E-K- [E / S] - [L / S] – E-X-
D-L-S-E with a Similarity Index equal to 4,21. 
However, when considering the epitopes ID: 2172, 
13913, 13914, 34828 the consensus is E-Q-Q-S-D-L-
E-Q-E-R-L-A-K-E-K-L-Q with an index higher than 9, 
and the first consensus is discarded. Unfortunately, the 
consensus epitope of antigens formed with more than 
47 epitopes could not be obtained as it was in the case 
of erythrocyte membrane protein 1, Merozoite surface 
protein 1, Merozoite surface protein 1 precursor, and 
ring-infested erythrocyte surface antigen.  
 
Table 1: Antigen, Epitope ID, consensus and Similarity Index of linear B cell epitope in Plasmodium 
falciparum (human host) 
Antigen Epitope ID   Consensus epitopes 
(X means any amino acid) 
Similarity 
Index 
101 kDa malaria 
antigen 
3367,13460,44251,70437,74430 N-X-S-X-N-K-K-K-K-[K/N]-
N 
4,54 
antigen 332, 
Ag332=Pf332 gene 
clone G1  
62347,62348,11652,11927,13834,26178,27395,
29409,34197,40575,58251,58957,60424,62354,
63344,63345,70536,70537 
E-E-G-S-V-T-E  
 
 
5,14 
antigen CARP  2803,9419,10581,13470,14891,28938,34935,42
148,43198,44153,44634,44740,45082,45197,45
198,45291,45823,46432,46479,46664,51737,58
759,59062,63723,70076,74131 
N-S-N-N 
 
 
1,5 
apical membrane 
antigen-1  
2163,11356,21373,27620,74433 E-X-I-S-H-X-X-K 
 
4,38 
Circumsporozoite  
protein 
14317,18741,20224,25768,42196,43117,74323,
12200,13438,24137,26865,32761,32769,32770,
43242,43247,43249,43255,43256,48618,49325,
756433,768466,768504,768505,768568 
N-P-D-P-N-A-N-P 
 
2,38 
Circumsporozoite  
protein precursor  
9424,9692,9694,15056,20166,26870,32573,369
12,43233,43240,43246,43248,43250,43337,451
10,46354,47747,48600,49324,62344,73090,982
N-A-N-P-N-A-N-P-N-A-N-P-
N-A-N 
1,87 
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15,742507,756260,756261,756262,756263,756
264,756359,756363,756411,756412 
 
cytoadherence linked 
asexual protein 
(CLAG)  
1925,4266,16090,16272,20683,22950,31638,38
442,45162,73279,75645 
F-I-D-K-E 
 
2,6 
Erythrocyte 
membrane protein 1  
8594,11043,18536,32472,34948,49140,72351,1
07935,141606,141609,141618,141625,141632,
141635,141659,141696,141732,141762,141781
,141785,181540,181544,181551,181556,18155
9,181564,181568,181569,181573, … (list is 
truncated) 
 
 
It could not be obtained  
 
Erythrocyte 
membrane protein, 
putative 
122259,122308,122325,122331,122338,122393
,122456,122460,122481,122578,466413 
L-T-S-[K/S]-D-E-E-D-I-I-K-
H-N-E-D-V-R-E-E-I-E-E 
 
5,63 
glutamate-richprotein 8942,10106,12059,12464,12465, 
12531,13688,13689,28742,31224,31225,33045,
36840,45563,48635,464223,466615,466616,46
6929,466930,466931,467355,467462,469456,4
72326 
E-D-D-K-N-E-K-V-E-H-E-I-
V-E-V-E-E-I-L-P-E 
0,81 
heat shock 70 
kDaprotein 
7498,7971,11185,21381,30289,32113,32114,32
596,39597,58859,68252,74095,74097 
[K/Y]-[E/K]-A-K-S-S-L-E-
[D/E]-T-C-I-K-[E/I/T/V]-K-
[L/N/T] 
1,43 
high molecular 
weight rhoptry 
protein-2  
463952,463953,464250,464291,467437,468427
,472211,472212 
T-Y-L-T-E-P-I-L-T-E 6,90 
Hypothetical protein 
PFB0145c 
12436,25526,25599,26453,26918,27699,35142,
37797,38274,44271,58709,67995 
I-N-[K/L]-L-N-[K/N/Q]-
[E/G]-K-K-K-L-K-K-K-I-E-E-
L-N-K-E-I-E-K-L 
4,28 
Liver stage antigen 
(12) 
2172,7763,7818,9449,11799,13913,13914,2493
0,26817,34828,40042,43702 
E-Q-Q-S-D-L-E-Q-ER-L-A-
K-E-K-L-Q 
9,64 
Major merozoite 
surface antigen 
22570,58841,71353,95818,125170 S-X-X-S-V-A-S-X-A-[E/S]-V-
A-S  
5,75 
Major surface antigen 
p190  
8351,11589,18758,20039,30477,58196,58266,6
1053,64002,67650,71536 
V-A-K-[E/G/P]-[S/V]-[P/S]-A 3,85 
Merozoite surface 
antigen 2  
13500,41662,55038,59922,62779,237695,2378
01,237804,237880,237961 
P-Q-N-T-S-D-S-Q-K-E-C-T  6,83 
Merozoite surface 
antigen 2 precursor  
1110,32454,32886,63534,66884, 
237625,237859,237860,237875,237941,237942
,237979 
[A/S/T]-[E/K/N]-[S/V]-P-T-E-
Q-Q-E-P-[N/S/T]-N-[K/S/V]-
P-[A/T]-E-Q 
3,88 
Merozoite surface 
protein 1  
4815,18759,20013,20042,22333,22809,22815,3
0479,35235,38186,44354,44355,52324,56142,5
6956,58058,58059,59932,62054,62055,64003,6
6238,67762,71533, … (list is truncated) 
 
 
It could not be obtained  
 
Merozoite surface 
protein 1 precursor  
2777,4417,6149,7639,8349,8350,11252,11439,1
1590,12289,18517,18761,18859,20012,20014,2
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2828,22841,30095,30476,30478,30480,30896,3
1214,32970,33715, … (list is truncated) 
It could not be obtained  
Merozoite surface 
protein 2  
780,21881,46258,142387,142414,142435,2377
08 
K-T-D-G-X-K-G-E-E-S-E 6,63 
Merozoite surface 
protein 3  
2167,11792,23729,42057,44750,47302,47303,7
3683,119616 
M-L-S-H-L-Y-V-S-S-K-D-K-
E-N-I-S-K-E-N-D  
5,25 
Merozoite surface 
protein 6  
11591,27084,38285,49034,57650,150372,15047
2 
I-[L/V]-G-X-W-E-F-[G/K]-
[G/N]-G-[A/I]-P  
4,33 
Merozoite surface 
protein-1  
101715,101759,101871,101907,101925,101997
,102082,125168,125169,8044,8738,10611,1278
1,12782,17492,28630,35438,36587,41286 
 
 
S-Q-H-Q-C-V-K-K-Q  1,66 
p101/acidic basic 
repeat antigen  
463650,463651,467193,468962,469233,469234
,472109,474217 
P-E-P-T-V-T-N-E-E  10,00 
PfEMP1  181590,181722,181787,181818,181823 L-S-A-T-D-V-X-L-E-K-I-A  4,91 
precursor for the 
major merozoite 
surface antigens  
101526,101528,101622,101623,101677,101756
,101848,101855,101920,101955,101971,10209
0,102131,13528,101466,101494,101506,10150
7,101508,101513, … (list is truncated) 
 
 
It could not be obtained  
 
Ring-infected 
erythrocyte surface 
antigen precursor  
886,7766,11823,19004,27463,27675,29294,304
74,32109,35817,43134,49801,59446,66932,675
62,68166,73584 
V-A-E-E-[H/Y]-V-E  2,85 
ring-infested 
erythrocyte surface 
antigen  
885,5761,8024,8730,9390,10164,11222,11813,1
1815,11816,11819,11820,11821,11822,11824,1
2518,12805,12888,27462,27674,30315,30473,3
2108,33177,33936, …  (list is truncated) 
 
 
It could not be obtained  
 
schizontegress 
antigen-1  
644539,647826,647940,650560,652461 N-D-X-A-I-Q-X-D-F-X-L-L-
D-N  
2,14 
serine-repeat antigen 
protein 
24874,32628,227031,227066,227109,227134,2
27145,227153,227174,227178,227216,227228,
227236,227262,227268,227270,227294,227308
,227318,227345, … (list is truncated) 
E-I-K-K-N-V-P-L-T  0,44 
VAR2CSA  141608,141610,141612,141613,141616,141617
,141627,141633,141645,141657,141658,14166
0,141663,141674,141676,141678,141681,1416
84,141686,141687, … (list is truncated) 
N-E-K-A 1,0 
 
Conclusion 
The present study allows the investigator to know the 
state of art of the linear B cells epitope in Plasmodium 
falciparum (human host) according to the information 
available in the Immune Epitope Database (IEDB). In 
this way, we can know the type of samples and the 
antigens that are more frequent in this type of study, as 
well as the journals and years of publication.  We 
deduce that 83% of the samples that have been 
analyzed come from Africa where the highest numbers 
of malaria cases are found. 
On the other hand, the small number of scientific 
publications on this subject is surprising despite the 
fact that malaria is a very old problem and it was in 
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1992 when the largest numbers of papers on the subject 
were published. Subsequently, the numbers of 
publications decrease with time until it becomes 
constant over time. This trend may reflect that the 
prediction and validation of B cell epitopes in 
Plasmodium falciparum is not a subject of current 
scientific research but rather that the scientific 
community may be using the epitopes already 
published in the scientific literature. This last 
observation could explain the tendency to use 
Circumsporozoite protein in B cell epitopes as well as 
DNAJ protein, unlike other antigens, as shown in Table 
1. 
 
Finally, the consensus epitopes of linear B cells 
epitopes were determined using the Similarity Index 
defined in the present paper in order to be able to 
compare a consensus with each other.In fact, the 
Similarity Index of PfEMP1 was 10,00 which means 
that said consensus presents no variability of the 
epitopes, however the consensus obtained from the 
serine-repeat antigen protein whose index was 0,44. 
That is a great variability according to the data in 
IEDB. The conclusion of this work is that the 
predictions must be validated with experimental results 
and thus be able to combat malaria caused by 
Plasmodium falciparum. 
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